Himalaya Wellness and CSIR CDRI Partner to Develop New PMOS Therapy

In October 2026, Himalaya Wellness Company entered into a licensing agreement with the Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, to develop a new evidence-based intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as Polycystic Ovary Syndrome (PCOS). The collaboration brings together CSIR-CDRI expertise in drug discovery and phytopharmaceutical research with Himalaya Wellness Company’s capabilities in herbal research, formulation development, and healthcare product development. The partnership is aimed at advancing research toward a potential therapy addressing the interconnected reproductive, metabolic, and endocrine aspects of PMOS.

PMOS is a complex condition involving multiple physiological pathways rather than a single organ or biological system. According to the report, the condition affects approximately one in eight women and more than 170 million people globally. Its combination of reproductive, metabolic, and endocrine characteristics can make disease management challenging and highlights the need for comprehensive approaches to women’s health. The collaboration between CSIR-CDRI and Himalaya is therefore focused on translating scientific research into a potential therapeutic option supported by evidence-based development.

Under the agreement, a standardized herbal extract developed by CSIR-CDRI scientists Dr. T.N. Narendrer and Dr. Rajesh Jha will be further advanced by Himalaya Wellness Company for its potential application in PMOS. Himalaya will focus on formulation development, clinical safety, and efficacy evaluation as the research progresses. This approach connected laboratory-level scientific discovery with product development and clinical evaluation, creating a pathway for a research-based intervention to move toward potential healthcare application.

The partnership also reflects the increasing role of collaborations between research institutions and healthcare companies in developing new therapeutic solutions. Academic and government-supported research institutes can contribute specialized scientific knowledge and drug discovery capabilities, while industry partners can provide expertise in formulation, development, commercialization, and product-focused research. By combining these capabilities, the collaboration aims to support the development of potential evidence-based solutions for an important women’s health challenge.

Focus on Comprehensive PMOS Management

The development program is particularly relevant because PMOS involves interconnected reproductive, metabolic, and endocrine factors. These overlapping dimensions can create complex healthcare requirements and may require approaches that address multiple aspects of the condition.

The CSIR-CDRI and Himalaya partnership is designed around this complexity. Rather than focusing solely on one symptom or biological pathway, the organization is investigating a standardized herbal extract for its potential application in PMOS. The development process will include formulation work as well as clinical safety and efficacy evaluation.

The focus on standardization is also important for the development of botanical and herbal-based healthcare interventions. A standardized extract can provide greater consistency in the composition of the material being evaluated during development. Combining such research with safety and efficacy assessment can help generate scientific evidence needed to determine the potential value of a therapeutic candidate.

The collaboration therefore represents an effort to connect traditional knowledge and herbal research with modern drug discovery and development approaches. It also demonstrates how scientific institutions and healthcare companies can work together to investigate new options for conditions where treatment needs remain significant.

Impact on the Women’s Health Market

The collaboration between Himalaya Wellness and CSIR-CDRI could contribute to the broader development of the women’s health market by increasing research activity focused in reproductive and metabolic disorders. PMOS represents a significant healthcare challenge because of its multiple physiological dimensions and its impact on women’s reproductive and metabolic health.

The development of new evidence-based interventions can create opportunitites for pharmaceutical, biotechnology, herbal healthcare, and research organizations to explore new therapeutic approaches. Increasing attention toward women’s health is also encouraging organization to investigate conditions that have historically required more targeted research and specialized treatment options.

The collaboration also highlights the importance if evidence generation in the herbal healthcare segment. Research-backed development can help organizations move beyond traditional use and investigate whether specific standardized extracts can provide clinically meaningful benefits for defined health conditions.

As healthcare systems increasingly emphasize personalized and comprehensive approaches, research into conditions involving multiple biological pathways may become an important area os innovation. PMOS, with its reproductive, metabolic, and endocrine components, provides an example of a condition where multidisciplinary research can contribute to the development of potential therapeutic solutions.

Impact on Pharmaceutical and Phytopharmaceutical Sector

The partnership is also significant for the pharmaceutical and phytopharmaceutical sector because it combines scientific drug discovery with herbal product development. CSIR-CDRI has expertise in drug discovery and phytopharmaceutical research, while Himalya contributes experience in herbal research and healthcare product development.

This combination can support the development of standardized botanical candidates through more structured research and development pathways. The collaboration may also encourage greater interaction between research institutions and private healthcare companies in the development of plant-based therapeutic candidates.

Phytopharmaceutical research has the potential to expand the range of therapeutic candidates being investigated for complex health conditions. However, translating a research discovery into a clinically useful therapy requires multiple stages of development, including formulation optimization, safety assessment, efficacy studies, regulatory evaluation, and appropriate clinical evidence.

The current agreement represents an early stage in this development pathway. The standardized herbal extract will be advanced by Himalaya, with the company focusing on formulation development, clinical safety, and efficacy evaluation.

This model of collaboration could provide a framework for future partnerships involving research institutes and healthcare companies seeking to develop evidence-based products from scientifically investigated natural compounds.

Role of Industry-Academia Collaboration

The Himalaya Wellness and CSIR-CDRI agreement demonstrates the growing importance of industry-academia and represents industry-academia partnerships in healthcare innovation. Research organizations often possess specialized capabilities in laboratory science, drug discovery, biological research, and early-stage development. Industry organizations, meanwhile, can provide resources and expertise required for formulation, product development, clinical evaluation, and market-oriented research.

The partnership brings these complementary capabilities together around a specific healthcare objective. CSIR-CDRI’s researchers developed the standardized herbal extract, while Himalaya will advance the candidate through formulation development and further evaluation.

Such collaboration can potentially shorten the gap between scientific discovery and practivle healthcare applications by allowing research findings to move into structured development programs. They can also support the translation of publicly funded or institutional research into products that may eventually be evaluated for broader healthcare use. 

For women’s health, these partnerships may be particularly valuable because complex conditions often require research involving multiple disciplines. Combining expertise in reproductive health, metabolic biology, pharmacology, phytopharmaceutical science, formulation, and clinical research can support more comprehensive development strategies.

Future Opportunities

The collaboration creates several potential opportunities for future research and development in women’s metabolic and reproductive health. One major opportunity lies in investigational investigating standardized plant-based extracts using modern scientific and clinical methodologies. Continued research could help establish their safety profiles, efficacy, appropriate formulations, and potential role in managing complex conditions.

Another opportunity is the development of additional evidence-based phytopharmaceutical candidates for women's health. As research organizations and healthcare companies increase collaboration, more scientifically evaluated botanical compounds could enter structured development pipelines.

The partnership may also encourage greater investment in research addressing conditions that combine reproductive, endocrine, and metabolic characteristics. Advances in clinical research, biomarker identification, formulation technologies, and evidence generation could further support the development of targeted interventions.

For the healthcare industry, the collaboration highlights the potential of combining established herbal research capabilities with modern drug discovery and clinical development processes. It may also contribute to broader acceptance of evidence-based approaches to herbal therapeutics when supported by appropriate scientific and clinical evaluation.

Conclusion

The licensing agreement between Himalaya Wellness Company and CSIR-CDRI marks a new collaboration focused on developing a potential therapy for Polyendocrine Metabolic Ovarian Syndrome. By combining CSIR-CDRI's drug discovery and phytopharmaceutical research capabilities with Himalaya's expertise in herbal research and product development, the organizations aim to advance a standardized herbal extract toward potential therapeutic application.

The initiative reflects the growing importance of evidence-based research in women's health and highlights the potential of industry-research partnerships to translate scientific discoveries into healthcare solutions. The next stages of formulation development, clinical safety assessment, and efficacy evaluation will be important in determining the potential of the intervention.

As research into women's reproductive and metabolic health continues to expand, collaborations that integrate drug discovery, phytopharmaceutical science, formulation expertise, and clinical evaluation could become an important part of healthcare innovation. The Himalaya Wellness and CSIR-CDRI partnership therefore represents a notable development in the ongoing search for new evidence-based approaches to complex women's health conditions.